METHOD FOR RESISTING AGING AND ENHANCING STEMNESS CHARACTERISTICS OF HUMAN MESENCHYMAL STEM CELLS

Abstract

Disclosed is a method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells. Through co-culture of immune cells in human peripheral blood and aging human mesenchymal stem cells in cell-to-cell contact mode, the method can significantly reverse the aging characteristics of the aging human mesenchymal stem cells, including reducing expressions of cell aging markers such as β-galactosidase, P21 and P16 proteins, and can regulate the cell cycle of the aging human mesenchymal stem cells, specifically by reducing the number of cells in G1 phase and increasing the number of cells in S phase. More importantly, the method can significantly enhance the stemness characteristics of the aging human mesenchymal stem cells, such as abilities of self-renewal, proliferation and multidirectional differentiation potential, and the cells obtained by the culture method are used to treat disease models, which is safe and effective. The present invention can be directly applied to long-term in vitro expansion of the human mesenchymal stem cells, solves the problem of cell aging in the expansion process, restores cell vitality, and improves clinical application effects.

Claims

1. A method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells, wherein the immune cells of human peripheral blood and human mesenchymal stem cells are co-cultured in cell-to-cell contact or non-contact mode.

2. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 1, wherein the human peripheral blood immune cells comprise human peripheral blood mononuclear cells, human peripheral blood monocytes and human peripheral blood lymphocytes.

3. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 2, wherein the human peripheral blood immune cells are the human peripheral blood lymphocytes.

4. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 1, wherein a ratio of the immune cells in human peripheral blood to the human mesenchymal stem cells is 1:1 to 400:1.

5. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 4, wherein a ratio of the immune cells in human peripheral blood to the human mesenchymal stem cells is 100:1 to 400:1.

6. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 1, wherein the method may significantly reverse the aging characteristics of the aging human mesenchymal stem cells, delay the aging of non-aging human mesenchymal stem cells, and reduce expressions of cell aging markers such as β-galactosidase, P21 and P16 proteins.

7. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 1, wherein the method regulates the cell cycle of the aging human mesenchymal stem cells, significantly reduces the proportion of cells in the G1 phase, increases the proportion of cells in the S phase, and reshapes the proliferation ability of the aging cells.

8. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 1, wherein the method significantly enhances the stemness characteristics of the aging human mesenchymal stem cells, comprising abilities of self-renewal, proliferation and multidirectional differentiation potential.

9. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 1, wherein the human mesenchymal stem cells obtained by co-culture are used to treat disease models without immune rejection.

10. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 1, wherein the method is applied to the long-term clinical expansion of the human mesenchymal stem cells in vitro to obtain a large number of high-quality human mesenchymal stem cells.

11. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 10, wherein the human peripheral blood immune cells comprise human peripheral blood mononuclear cells, human peripheral blood monocytes and human peripheral blood lymphocytes.

12. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 11, wherein the human peripheral blood immune cells are the human peripheral blood lymphocytes.

13. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 10, wherein a ratio of the immune cells in human peripheral blood to the human mesenchymal stem cells is 1:1 to 400:1.

14. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 13, wherein a ratio of the immune cells in human peripheral blood to the human mesenchymal stem cells is 100:1 to 400:1.

15. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 10, wherein the method may significantly reverse the aging characteristics of the aging human mesenchymal stem cells, delay the aging of non-aging human mesenchymal stem cells, and reduce expressions of cell aging markers such as β-galactosidase, P21 and P16 proteins.

16. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 10, wherein the method regulates the cell cycle of the aging human mesenchymal stem cells, significantly reduces the proportion of cells in the G1 phase, increases the proportion of cells in the S phase, and reshapes the proliferation ability of the aging cells.

17. The method for resisting aging and enhancing stemness characteristics of human mesenchymal stem cells according to claim 10, wherein the method significantly enhances the sternness characteristics of the aging human mesenchymal stem cells, comprising abilities of self-renewal, proliferation and multidirectional differentiation potential.

18. The method for resisting aging and enhancing sternness characteristics of human mesenchymal stem cells according to claim 10, wherein the human mesenchymal stem cells obtained by co-culture are used to treat disease models without immune rejection.

Description

BRIEF DESCRIPTION OF DRAWINGS

[0019] FIG. 1 illustrates the phenotype identification of human MSC (taking human amniotic membrane MSC as an example). (A) flow cytometry to detect surface molecular markers; (B) immunocytochemical staining to detect vimentin and keratin CK19. Here MSC the abbreviation of mesenchymal stem cells.

[0020] FIG. 2 shows the changes of the number of β-galactosidase positive cells (aging cells) after PBMC with different cell ratios are co-cultured with aged MSC. Here MSC means mesenchymal stem cells; PBMC means peripheral blood mononuclear cells.

[0021] FIG. 3 shows the changes of the number of β-galactosidase positive cells (aged cells) after PBMC and aged MSC are co-cultured in different ways (contact and non-contact). Here MSC means mesenchymal stem cells; PBMC means peripheral blood mononuclear cells.

[0022] FIG. 4 shows the changes of the number of β-galactosidase positive cells (aged cells) after PBMC from different donor ages are co-cultured with aged MSC. Here MSC means mesenchymal stem cells; PBMC means peripheral blood mononuclear cells.

[0023] FIG. 5 shows the changes of the number of β-galactosidase positive cells (aged cells) after different immune cells in human peripheral blood are co-cultured with aged MSC. Here MSC means mesenchymal stem cells.

[0024] FIG. 6 shows the changes of the number of β-galactosidase positive cells (aged cells) after PBL are co-cultured with human umbilical cord mesenchymal stem cells. Here PBL means peripheral blood lymphocytes.

[0025] FIG. 7 shows the changes of the number of β-galactosidase positive cells (aged cells) after PBL are co-cultured with human umbilical cord blood mesenchymal stem cells. Here PBL means peripheral blood lymphocytes.

[0026] FIG. 8 shows the changes in the expression of the aged markers P21 and P16 proteins in the aged MSC detected by western blotting after PBL is contacted and co-cultured with the aged MSC. Here MSC means mesenchymal stem cells; PBL means peripheral blood lymphocytes.

[0027] FIG. 9 shows the flow cytometry analysis of the cell cycle changes of the aged MSC after the PBL is contacted and co-cultured with the aged MSC. Here MSC means mesenchymal stem cells; PBL means peripheral blood lymphocytes.

[0028] FIG. 10 shows the changes in the expansion ability of the aged MSCs detected by the EDU kit after the PBL is co-cultured with the aged MSCs. Here MSC means mesenchymal stem cells; PBL means peripheral blood lymphocytes; EDU means 5-ethynyl-2′-deoxyuridine.

[0029] FIG. 11 shows the cloning ability experiment of aged MSCs after 15 days of co-culturing PBL with aged MSCs. Here MSC means mesenchymal stem cells; PBL means peripheral blood lymphocytes.

[0030] FIG. 12 shows the changes in the expression of proliferating cell nuclear antigen PCNA and the stem transcription factor Oct4 in the aged MSCs detected by western blotting after PBL is contacted and co-cultured with aged MSCs. Here MSC means mesenchymal stem cells; PBL means peripheral blood lymphocytes.

[0031] FIG. 13 shows the changes in the ability of aged MSCs to differentiate into osteogenic, cartilage and adipocytes after PBL is co-cultured with aged MSC. Here MSC means mesenchymal stem cells; PBL means peripheral blood lymphocytes.

[0032] FIG. 14 shows the effect of β-galactosidase staining on delaying MSC aging after long-term contact of PBL and non-aged MSC for 12 days. Here MSC means mesenchymal stem cells; PBL means peripheral blood lymphocytes.

[0033] FIG. 15 shows the levels in the expression of the aged markers P21 and P16 proteins in the MSC detected by western blotting after PBL is contacted and co-cultured with the non-aged MSC for a long time of 12 days. Here MSC means mesenchymal stem cells; PBL means peripheral blood lymphocytes.

[0034] FIG. 16 shows the efficacy evaluation of MSCs obtained after PBL and aged MSCs are contacted and co-cultured on ulcerative colitis mouse models. (A) mouse body weight change; (B) mouse disease activity index (DAI) score; (C) pathological observation; (D) pathological score. Here MSC means mesenchymal stem cells; PBL means peripheral blood lymphocytes.

DETAIL DESCRIPTIONS OF EMBODIMENTS

[0035] In order to more fully explain the implementation of the present invention, and that the objectives, technical schemes and advantages of the present invention will become more apparent, the technical solutions of the present invention will be described in more detail with reference to the drawings and examples above. MSCs from different tissues have no effect on the results (see Embodiment 7). The present embodiment mainly uses human amniotic membrane MSCs for illustration. It should be understood that the specific embodiments described herein are only for illustrating but not for limiting the present invention. In addition, the embodiment of the present invention passed the review of the ethics committee of the Affiliated Hospital of Zunyi Medical College (ethics review number: KLLY-2017-003).

Embodiment 1: Isolation, Culture and Identification of Human Mesenchymal Stem Cells

[0036] The amniotic membrane tissue is stripped from the fresh placenta of healthy term cesarean section, and the residual blood stains and mucus are repeatedly washed with D-PBS solution containing 1% bi-antibody (final concentration including penicillin of 100 IU/mL, and streptomycin of 100 IU/mL; freshly prepared before use). After cutting the amniotic membrane to a size of about 1 cm.sup.2, it is divided into 50 mL centrifuge tubes, and then 0.05% trypsin digestion solution containing 0.02% EDTA-2Na that is about 2 times the volume of the amniotic membrane tissue is added for digesting in a constant temperature water bath at 37° C. at 185 rpm for about 30 minutes, filtering with 300 mesh stainless steel filter, and removing the supernatant; then, the above steps are repeated. The digested amniotic membrane is washed with D-PBS containing 1% bi-antibody once, and an equal volume of 0.5 mg/mL type II collagenase digestion solution containing 0.05 mg/mL DNase I is added for rotating and digesting at 190 rpm at 37° C. for 1 to 1.5 h until the amniotic membrane fragments are completely digested into flocculent, followed by filtering with a 300 mesh filter and collecting cell filtrate for centrifuging at 1500 rpm for 10 minutes; then, the supernatant is removed, and the cell pellet is the human amnion-derived mesenchymal stem cells (hA-MSC). The cells are resuspended in low-glucose DMEM complete medium containing 10% FBS, plated in 75-cm.sup.2 cell culture flasks, cultured at a constant temperature with 5% CO.sub.2 and 85-100% air saturated humidity at 37° C., and subcultured when the confluence of the cells reaches 80% or more, so as to collect the passage 3 (P3) or passage 9 (P9) cells for experiments. Further, the human umbilical cord-derived mesenchymal stem cells (human umbilical cord-derived mesenchymal stem cells, hUC-MSC) are separated from fresh umbilical cord tissue using the tissue block adhesion method, and the human umbilical cord blood-derived mesenchymal stem cells (human umbilical cord blood-derived mesenchymal stem cells, hUCB-MSC) are separated from fresh cord blood by the density gradient centrifugation; all are purified by trypsin, and the P3 cells are collected for experiments. These mesenchymal stem cells highly express CD90, CD105, CD73, CD44 and CD29 and other mesenchymal cell surface molecules, do not express hematopoietic stem cell markers such as CD34, CD11b, CD19, CD45 and HLA-DR and MHC class II cell surface molecules (FIG. 1A). The results of immunocytochemical staining show that the cells highly express vimentin, a mesenchymal cell marker, but do not express cytokeratin 19 (CK19), a marker of epithelial cells (FIG. 1B). They have a typical mesenchymal cell phenotype.

Embodiment 2: Isolation of Human Peripheral Blood Immune Cells

[0037] Fresh peripheral blood from a normal physical examination population is taken for diluting it with an equal volume of sterile D-PBS. An appropriate amount of Histopaque-1077 is added to a 15 mL centrifuge tube, and an equal volume of sterile D-PBS diluted blood is slowly added along the tube wall for centrifuging at 2000 rpm for 20 min; the middle albuginea layer is extracted, and an equal volume of sterile D-PBS is added for centrifuging at 1500 rpm for 10 min; washing is performed repeatedly with sterile D-PBS once, and the supernatant is discarded; the cell pellet is suspended in DMEM medium containing 10% FBS and low glucose to obtain PBMC immune cells. With the characteristics of peripheral blood mononuclear cells (PBM) that are easy to adhere to and grow on plastic cell culture plates, the PBM and peripheral blood lymphocytes (PBL) are separated from the above PBMC.

Embodiment 3: Comparison the Reversal Effects on Aged Cells of Contact Co-Culturing PBMC with the Aged MSC at Different Cell Ratios

[0038] The human amniotic membrane MSCs that are continuously expanded to the P9 in vitro and have replicative aging is taken for inoculating on a 12-well cell culture plate at a density of 10.sup.4/well, and the freshly-isolated PBMC is added after 16 h, wherein the density of PBMC is 10.sup.4, 10.sup.5, 10.sup.6, 2×10.sup.6, 3×10.sup.6 and 4×10.sup.6/well respectively, and the PBMC and the MSC are co-cultured at cell ratios of 1:1, 10:1, 100:1, 200:1, 300:1 and 400:1. After PBMC and MSC are co-cultured for 72 hours, β-galactosidase staining is used to detect the number of positive aged MSCs. The results (FIG. 2) show that the rate of β-galactosidase positive cells in the control group of aged MSCs cultured to the 10th generation (hereinafter referred to as “MSC-10”) is (77.07±7.23)%, and when PBMC:MSC-10=1:1 or 10:1, the positive rate of β-galactosidase does not change significantly as compared with the aging control group; when PBMC:MSC-10 reaches 100:1, the positive rate of β-galactosidase begins to decrease significantly, from 77.07% to 22.61%, and when the cell ratio of co-culturing PBMC with aged MSC continues to increase, the positive rate of β-galactosidase still shows a downward trend as compared with the control group; the effect is best when the cell ratio is 300:1, and the rate of β-galactosidase positive cells is only (20.07±3.07)% (Table 1). Therefore, when PBMC and MSC are co-cultured at a cell ratio of 100:1-400:1, the aged MSC may be significantly rejuvenated, showing the effect of reversing aging.

[0039] Table 1 is β-galactosidase staining to detect the reversal effect on aged cells of PBMC and aged MSC contact co-culturing at different cell ratios.

TABLE-US-00001 cell ratios in co-culturing rate of β-galactosidase positive (PBMC:MSC-10) cells (%)  1:1 75.8 ± 1.47   10:1 74.19 ± 2.94  100:1 22.61 ± 3.26** 200:1 22.58 ± 2.27** 300:1 20.07 ± 3.07** 400:1 20.92 ± 2.55** Note: The rate of β-galactosidase positive cells in the MSC-10 group is (77.07 ± 7.23) %, and compared with MSC-10, **p < 0.01. Here MSC means mesenchymal stem cells; MSC-10 means 10th generation mesenchymal stem cells; PBMC means peripheral blood mononuclear cells.

Embodiment 4: Comparison the Reversal Effects on Aged Cells of Contact and Non-Contact Co-Culturing PBMC and the Aged MSC

[0040] The human amniotic membrane MSCs that are continuously expanded to the P9 in vitro and have replicative aging is taken for inoculating into the lower chamber of Transwell (Corning, 3401) at a density of 10.sup.4/well, and adding 10.sup.6 freshly-separated PBMCs in the lower or upper chambers respectively to be co-cultured with MSCs; after 72 h, the cells in the lower chamber are observed and β-galactosidase staining is performed to detect aged positive cells. The results (FIG. 3) show that both contact and non-contact co-culturing of PBMC and MSC may significantly reduce the positive staining rate of β-galactosidase in aged MSCs, make aged cells younger, and reverse aging. The effect in reversing of the contact co-culturing is better than that of the non-contact co-culturing.

Embodiment 5: Comparison the Reversal Effects on Aged Cells of Contact Co-Culturing PBMC from Different Donor Ages and Aged MSC

[0041] The human amniotic membrane MSCs that are continuously expanded to the P9 in vitro and have replicative aging is taken for inoculating on a 12-well cell culture plate at a density of 10.sup.4/well, and freshly-separated PBMCs from different age groups are added after 16 h. After aged MSC (MSC-10) and PBMC are co-cultured for 72 h, the aged positive cells are detected by 3-galactosidase staining. The results (FIG. 4) show that the positive rate of β-galactosidase staining in the aged MSC group is (69.75±4.79)%; compared with the above, PBMC from different donor ages may significantly reduce the positive rate of β-galactosidase staining in the co-culture system when added to the aged MSC group, rejuvenating aged cells with effects in reversing aging. However, the mean value of the rate of β-galactosidase staining positive cells after co-culturing PBMCs from donors of different ages and aged MSCs ranges from (19.56±4.20)% to (20.84±4.35)% (Table 2), and there is no statistical difference between the groups in the effects in reversing aging.

[0042] Table 2 is β-galactosidase staining to detect the reversal effect on aged cells of contact co-culturing PBMC from different donor ages and the aged MSC.

TABLE-US-00002 age group of immune cell number of rate of β-galactosidase positive donor (years) cases cells (%) 21-30 10 19.90 ± 2.71** 31-40 10 20.84 ± 4.35** 41-50 10 19.56 ± 4.20** 51-60 10 20.35 ± 5.48** 61-70 10 20.74 ± 4.26** 71-80 10 22.27 ± 3.36** Note: The rate of β-galactosidase positive cells in the MSC-10 group is (69.75 ± 4.79) %, and compared with MSC-10, **p < 0.01. Here MSC means mesenchymal stem cells; MSC-10 means 10th generation mesenchymal stem cells; PBMC means peripheral blood mononuclear cells.

Embodiment 6: Comparison the Reversal Effects on Aged Cells of Contact Co-Culturing Different Immune Cells from Human Peripheral Blood and Aged MSC

[0043] Density gradient centrifugation is used to separate PBMC from the peripheral blood of the physical examination population, and seeded on a 12-well cell culture plate at a density of 2×10.sup.6/well; after 2 h, with the characteristics of PBM that it is easy to adhere to the plastic culture plate to grow on the wall, the PBM and the PBL are separated from the PBMC. Further, the human amniotic membrane MSCs that are continuously expanded to the P9 in vitro and have replicative aging is taken for inoculating respectively on 12-well cell culture plates containing PBMC, PBM and PBL at a density of 10.sup.4/well, and β-galactosidase staining is used to detect the effects of PBMC, PBM and PBL on aged MSCs in the co-culture system after 72 h of co-culturing. The results (FIG. 5) show that co-culturing PBMC, PBM and PBL with aged MSC may reduce the positive rate of β-galactosidase staining (aged cells), make aged cells younger, and have the effect of reversing aging; the rate of β-galactosidase positive cells in the aged cell MSC-10 group is (71.60±2.49)%, and the rates of β-galactosidase positive cells measured by co-culturing PBMC, PBM and PBL with the aged cell MSC-10 group are (17.52±2.24)%, (33.67±4.77)% and (11.39±2.17)% (Table 3), i.e., the effect of these immune cells in reversing aging is: PBL>PBMC>PBM.

[0044] Table 3 is β-galactosidase staining to detect the reversal effect on aged cells of different immune cells and aged MSC contact co-culturing.

TABLE-US-00003 rate of β-galactosidase positive Groups cells (%) MSC-10 71.60 ± 2.49 PBM + MSC-10 33.67 ± 4.77** PBL + MSC-10 11.39 ± 2.17**.sup.##& PBMC + MSC-10 17.52 ± 2.24**.sup.## Note: Compared with MSC-10, **p < 0.01; compared with PBM + MSC-10, .sup.##p < 0.01; compared with PBMC + MSC-10, .sup.&p < 0.05. Here MSC means mesenchymal stem cells; MSC-10 means 10th generation mesenchymal stem cells; PBMC means peripheral blood mononuclear cells; PBM means peripheral blood mononuclear cells; PBL means peripheral blood lymphocytes.

Embodiment 7: Comparison the Reversal Effects on Aged Cells of Contact Co-Culturing PBL and Aged MSCs Derived from Umbilical Cord and Cord Blood

[0045] The human umbilical cord-derived mesenchymal stem cells (hUC-MSC) are separated from fresh umbilical cord tissue using the tissue block adhesion method, and the human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSC) are separated from fresh cord blood by the density gradient centrifugation; all are purified by trypsin, and the P9 cells are collected for experiments. The P9 hUC-MSC and hUCB-MSC with replicative aging are taken for inoculating in a 12-well cell culture plate at a density of 10.sup.4/well, and the freshly-separated PBL is added after 16 h for co-culturing for 72 h; then, β-galactosidase staining is used to detect the ability of PBL to reverse the aging characteristics of aged hUC-MSC and aged hUCB-MSC. The results show that similar to the results of contact co-culturing PBL and aged human amniotic membrane MSC, the contact co-culture of PBL and the aged hUCMSC may significantly reverse the aging characteristics of aged hUC-MSC (FIG. 6); similarly, the contact co-culture of PBL and the aged hUCB-MSC may also significantly reverse the aging characteristics of aged hUCB-MSC (FIG. 7). Therefore, the effect of PBL in reversing the aging characteristics of aged human MSC is not limited to the tissue source of MSC. It has the effect of reversing aging and rejuvenating other solid tissues including blood-derived MSC. The following, with the human amniotic membrane MSC as an example, describes the effects of co-culturing PBL in reversing the aging of the aged MSC and delaying long-time in vitro expansion aging of the non-aged MSC, while evaluating the biological characteristics and functions.

Embodiment 8: Contact Co-Culturing PBL and Aged MSC May Reduce the Expression of Aged Marker Proteins P21 and P16

[0046] The MSCs that have been continuously expanded to the P9 in vitro and have replicative aging are taken for inoculating in a cell culture dish with a diameter of 10 cm at a density of 2×10.sup.5, and the freshly-separately PBL is added after 16 h for co-culturing for 72 h; then the total cell protein is extracted, and western blotting is used to analyze the expression of aged markers P21 and P16 proteins. The results (FIG. 8) show that co-culturing PBL and aged MSC may significantly reduce the expression of aged marker proteins P21 and P16 of MSC in the co-culture system.

Embodiment 9: Contact Co-Culturing PBL and Aged MSC May Regulate the Cell Cycle of Aging MSC

[0047] The MSCs that have been continuously expanded to the P9 in vitro and have replicative aging are taken for inoculating in a cell culture dish with a diameter of 10 cm at a density of 2×10.sup.5, and the freshly-separately PBL is added after 16 h for co-culturing for 72 h; then the cells are washed 6 times with sterile D-PBS, trypsinized and then centrifuged at low speed to collect the cells, and the DNA content detection kit (Solarbio, Calif. 1510) is used to detect the cell cycle. The results (FIG. 9) show that co-culturing PBL and aged MSC may significantly regulate the cell cycle of MSC in the co-culture system, specifically represented by significantly reducing the cell ratio in G1 phase and increasing the cell ratio in S phase, suggesting that aged MSC cells restart division and proliferation.

Embodiment 10: Contact Co-Culturing PBL and Aged MSC May Reshape the Expansion Ability and Self-Renewal Ability of Aged MSC

[0048] The MSCs that are continuously expanded to the P9 in vitro and have replicative aging is taken for inoculating on 24-well cell culture plate at a density of 3×10.sup.3/well, and after 16 h, freshly isolated PBL is added and co-cultured for 72 h; then, EDU kit is used to detect the effect of PBL on the expansion of aged MSC. The results (FIG. 10) show that after PBL and aged MSC are co-cultured, the EDU positive cell rate increases from 3.54% to 12.31% (Table 4), which significantly improves the expansion ability of aged MSC.

[0049] Table 4 shows reshaping the expansion ability of aged MSC detected by EDU staining in case where PBL and aged MSC are co-cultured in the contact way.

TABLE-US-00004 Groups EDU positive cell rate (%) MSC-10 3.54 ± 0.47  PBL + MSC-10 12.30 ± 0.91** Note: Compared with MSC-10, **p < 0.01. Here MSC means mesenchymal stem cells; MSC-10 means 10th generation mesenchymal stem cells; PBL means peripheral blood lymphocytes; EDU means 5-ethynyl-2′-deoxyuridine.

Embodiment 11: Contact Co-Culturing PBL and Aged MSC May Enhance the Cloning Ability of Aged MSC

[0050] The MSCs that are continuously expanded to the P9 in vitro and have replicative aging is taken for seeding in a cell culture dish with a diameter of 10 cm at a density of 200 cells per dish, and after 16 h, freshly isolated PBL is added and the medium is changed every 6 days; after 15 days of co-culturing, the cell colony formation of aged MSCs is observed by crystal violet staining and recorded by taking pictures. The results (FIG. 11) show that after 15 days of co-culturing PBL and aged MSC, a significant increase in cell colonies is observed, and the colony formation rate increases by more than 10 times (Table 5). Therefore, this method may reshape the self-renewal ability of aged MSC.

[0051] Table 5 shows enhancement of the cloning ability of aged MSC detected by crystal violet staining in case where PBL and aged MSC are co-cultured in a contact way.

TABLE-US-00005 Groups clone formation rate (%) MSC-10 1.33 ± 0.58  PBL + MSC-10 28.33 ± 3.51** Note: Compared with MSC-10, **p < 0.01. Here MSC means mesenchymal stem cells; MSC-10 means 10th generation mesenchymal stem cells; PBL means peripheral blood lymphocytes.

Embodiment 12: Contact Co-Culturing PBL and Aged MSC May Enhance the Expression of PCNA and Stem Transcription Factor Oct4 in Aged MSC

[0052] The MSCs that have been continuously expanded to the P9 in vitro and have replicative aging are taken for inoculating in a cell culture dish with a diameter of 10 cm at a density of 2×10.sup.5, and the freshly-separately PBL is added after 16 h for co-culturing for 72 h; then the total cell protein is extracted, and Western blotting is used to analyze the expression of proliferating cell nuclear antigen PCNA and stem transcription factor Oct4. The results (FIG. 12) show that after PBL and the aged MSC are co-cultured, the expression level of the proliferating cell nuclear antigen PCNA and the stemness characteristic transcription factor Oct4 in aged MSC may be significantly enhanced.

Embodiment 13: Contact Co-Culturing PBL and Aged MSC May Improve the Multi-Directional Differentiation Ability of Aged MSC

[0053] The MSCs that are continuously expanded to the P9 in vitro and have replicative aging is taken for inoculating in 6-well cell culture plate at a density of 2×10.sup.4/well, and after 16 h, freshly isolated PBL is added and co-cultured for 72 hours; then, when the cell confluence reaches 80%, the medium is replaced with osteogenic and chondrogenic differentiation medium, and when the cell confluence reaches 100%, the medium is replaced with adipogenic differentiation medium. During the whole process of induction and differentiation, the medium is changed every 3 days, and on 21th day, toluidine blue staining is used to detect the production of glycosaminoglycans in the extracellular matrix of chondrogenic differentiation, alizarin red S staining is used to determine the formation of osteogenic differentiation calcified nodules, and oil red 0 staining is used to determine the formation of adipogenic lipid droplets. The results (FIG. 13) show that Toluidine Blue staining detects that the aged MSC after PBL treatment had a strong ability to produce glycosaminoglycans in cartilage matrix; Alizarin Red S staining shows stronger calcium nodule formation ability; Oil Red 0 staining shows more bright red lipid droplets are formed. Therefore, the method has the ability to enhance the differentiation ability of aged MSCs into osteogenic, adipogenic and chondrogenic.

Embodiment 14: Long-Term Co-Culturing PBL and Non-Aged MSC May Delay MSC Aging

[0054] The P3 MSC in the logarithmic growth phase is taken for inoculating in a 6-well cell culture plate at a density of 10.sup.3/well; after 16 h, freshly separated PBL is added, and the liquid is changed every 4 days; after continuous culture for 12 days, the cells are taken out, and aging positive cells are detected by β-galactosidase staining. The results (FIG. 14) show that after 12 days of continuous in vitro culture, the MSCs appear flat and wide in cell bodies, and show a positive staining rate of β-galactosidase of 68.5%, suggesting that the long-term in vitro expansion and culture will lead to the aging of hAMSCs. However, after 12 days of co-culturing PBL and MSC, the cell morphology still shows a long spindle-shaped spiral growth, and the positive staining rate of β-galactosidase is only 3.9%. Therefore, the method may significantly delay the occurrence of MSC aging during long-term in vitro expansion.

Embodiment 15: Long-Term Contact Co-Culturing PBL and Non-Aged MSC May Significantly Reduce the Expression of Aged Marker Proteins P21 and P16 in MSC

[0055] The P3 of MSCs in the logarithmic growth phase are taken for inoculating in a cell culture dish with a diameter of 10 cm at a density of 10.sup.4, and the freshly-separately PBL is added after 16 h; the medium is changed every 4 days, and after 12 days of continuous culture, the total cell protein is extracted, and western blotting is used to analyze the expression of aged marker proteins P21 and P16. The results (FIG. 15) show that after PBL and MSC are co-cultured for 12 days, the expression levels of aged marker proteins P21 and P16 of MSC are significantly lower than those in the non-co-culture group.

Embodiment 16: Therapeutic Effect of MSC Obtained by Expansion with Contact Co-Culturing PBL and Aged MSC on Disease Models

[0056] A mouse model of ulcerative colitis is constructed by free diet 3% DSS, and C57 mice aged 5-7 weeks are randomly divided into 4 groups, a total of 40 mice, 10 mice in each group, which are marked with Normal, DSS, DSS+MSC-10 and DSS+PBL+MSC-10 respectively. The DSS+MSC-10 group and the DSS+PBL+MSC-10 group are treated with P10 and lymphocytes by intraperitoneal injection of P10 MSCs (1×10.sup.7/head) after 72 hours at the start of feeding DSS. Normal and DSS mice are injected with equal volume of sterile PBS at the same time. During the observation, the weight is regularly measured and the death situation is recorded every day, as well as observing whether there are loose stools, bloody stools, etc. The disease activity index (DAI) is calculated based on the weight, diarrhea, blood in the stool, and death of the mouse. Ten days after injection of MSC, all the mice are sacrificed, and the colon segment is fixed with 4% paraformaldehyde overnight at room temperature, embedded in paraffin, and cut into 4 μm sections for HE staining. The inflammatory cell infiltration and crypt and goblet cell structure of colon tissue are observed under a microscope, and histopathological score is performed. The results show that on the 5th day of feeding DSS, the mice begin to show severe inflammatory colitis symptoms, including weight loss, loose stools, bloody stools, etc., and die on the 7th day (FIG. 16); histological analysis shows that DSS feeding causes severe inflammation and damage to the colonic mucosa of mice (FIGS. 16C and D). The therapeutic effect of P10 MSC on mice with ulcerative colitis is similar to that of DSS group, wherein there is severe weight loss and bloody stools, and histopathological observation of the colon shows severe inflammatory cell infiltration and loss of crypt and goblet cell structure. However, injecting P10 MSCs obtained by expansion with co-culturing PBL and aged MSCs may significantly reduce the weight loss, bloody stools, colon inflammation and damage induced by DSS in mice (FIG. 16), without immune rejection and causing death, with the obvious therapeutic effect.